library.onepin.app/gnrh-gonadorelin Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Hormonal

Hormonal Peptide Not FDA-approved · investigational

GnRH (Gonadorelin)

Gonadorelin · GnRH · Lutrelef · Cystorelin · Factrel

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH) produced by the hypothalamus. It binds to GnRH receptors on the anterior pituitary gland, stimulating the synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These gonadotropins are essential for reproductive function, stimulating testosterone production in males and ovulation in females.,Gonadorelin has been FDA-approved since the 1980s for diagnostic evaluation of pituitary gonadotroph function and for the treatment of primary hypothalamic amenorrhea. In clinical practice, pulsatile GnRH administration via pump can restore normal pulsatile gonadotropin secretion and fertility. It is also used off-label in male hormone optimization protocols to maintain endogenous testosterone production and fertility during testosterone replacement therapy.,Due to its extremely short half-life (2 to 4 minutes), gonadorelin must be administered in pulsatile fashion or at frequent intervals to mimic the body's natural secretion pattern. Continuous or high-dose administration paradoxically suppresses LH and FSH through receptor downregulation, which is the basis for GnRH agonist drugs used in prostate cancer and endometriosis.

Quick Start
Route
Subcutaneous (SubQ)
Start low
100-200mcg
Frequency
2-3x/week
Timing
No specific requirement

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
100-200mcg · Subcutaneous (SubQ) · 2-3x/week
Lowest starting point. Hold about a week to assess tolerance before stepping up.
100-200mcg
2-3x/week
Intermediate
Pulsatile HPTA Stimulation
100-200 mcg · SubQ · 2x Weekly
human clinical trial · FDA Factrel label
100-200 mcg
2x Weekly
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

Binds to GnRH receptors on anterior pituitary gonadotroph cells, activating phospholipase C signaling cascade, which triggers the release of stored LH and FSH into the bloodstream.,Pulsatile administration maintains receptor sensitivity and mimics physiological GnRH secretion patterns, sustaining gonadotropin output. Continuous exposure causes receptor downregulation and paradoxical suppression.,Downstream effects include stimulation of Leydig cells (testosterone production) and Sertoli cells (spermatogenesis) in males, and follicular development and ovulation in females.

Binds to GnRH receptors on anterior pituitary gonadotroph cells, activating phospholipase C signaling cascade, which triggers the release of stored LH and FSH into the bloodstream.,Pulsatile administration maintains receptor sensitivity and mimics physiological GnRH secretion patterns, sustaining gonadotropin output. Continuous exposure causes receptor downregulation and paradoxical suppression.,Downstream effects include stimulation of Leydig cells (testosterone production) and Sertoli cells (spermatogenesis) in males, and follicular development and ovulation in females.

02

What to expect

Early
Days 1–7

Days 1-7: Acute LH/FSH pulses occur within minutes of each injection. No subjective effects typically noticed.

03

Evidence

HumanPresent
AnimalStrong
In-vitroPresent
2019The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men · Mao JF, Liu ZX, Nie M, et al, American Journal of Men's Health ↗trial registry
2020Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism · Salonia A, Rastrelli G, Hackett G, et al, Yonsei Medical Journal ↗review
2013An update on male hypogonadism therapy · Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI, Expert Opinion on Pharmacotherapy ↗review
04

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

AnastrozoleAI manages estradiol from gonadorelin-stimulated testosterone production - no direct interaction
DHEANo pharmacological conflict - DHEA provides adrenal androgen support independent of GnRH axis
KisspeptinKisspeptin is upstream of GnRH release - concurrent use may be redundant but not harmful
Injectable B-ComplexNo interaction - administer in separate syringes

Keep separate

Triptorelin (continuous)Continuous GnRH agonist exposure causes receptor downregulation and HPG axis suppression - opposes gonadorelin's purpose of maintaining pulsatile stimulation
Any compound in same syringeGonadorelin is a fragile peptide that should be administered alone - do not mix in the same syringe with other peptides
05

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~2-4 min
Peak · Tmax
~10-20 min SubQ
Elimination
~15-30 min
Activity
1-4 hours (LH/FSH pulse)

Storage. Store refrigerated at 2-8C. Protect from light. Reconstituted solution stable for up to 14 days refrigerated.

06

Regulatory status

FDA-approved (Factrel, Lutrepulse) for diagnostic use and treatment of hypothalamic amenorrhea. Off-label use for fertility preservation during TRT.

Put it to work

Calculate, log & track

Open GnRH (Gonadorelin) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open GnRH (Gonadorelin) in the app →

Go deeper

The guide & community

The complete GnRH (Gonadorelin) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community